Cipla submits application with USFDA for generic version of asthma drug

Cipla submits application with USFDA for generic version of asthma drug The company has submitted an abbreviated new drug application (ANDA) for Fluticasone propionate and Salmeterol inhalation powder (100/50 mcg, 250/50 mcg and 500/50 mcg) to the US Food and Drug Administration (USFDA), Cipla said in a regulatory filing.

No comments:

Post a Comment